Navigation Links
Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
Date:11/21/2011

TARRYTOWN, N.Y., Nov. 21, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it has elected Marc Tessier-Lavigne, Ph.D. to fill a new seat on its expanded Board of Directors.  Dr. Tessier-Lavigne is President of The Rockefeller University in New York City, one of the world's preeminent medical research institutions.  Prior to his appointment at Rockefeller in 2011, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc.

"Marc is an ideal individual to join the Regeneron board of directors as he is a renowned scientist who also has an outstanding track record for leading drug-discovery programs at Genentech for most of the last decade," said P. Roy Vagelos, M.D., Chairman of the Regeneron Board of Directors.  "We are extremely pleased to add his expertise to our Board at a time when Regeneron is transforming into a fully integrated biotechnology company."

"I admire Regeneron's high-caliber science and its success in discovering and developing innovative therapeutics," said Dr. Tessier-Lavigne.  "I am honored to join the Regeneron board of directors and look forward to working with its distinguished members to help guide scientific and product development decisions at the company over the coming years.  I am also pleased to contribute to a biotechnology leader that is New York based."

A world leader in the study of brain development, Dr. Tessier-Lavigne has pioneered the identification of the molecules that direct the formation of connections among nerve cells to establish neuronal circuits in the mammalian brain and spinal cord.  The mechanisms he has identified are important for understanding how the human brain forms during normal development, and are increasingly being implicated in a variety of other processes, including neurodegenerative diseases.

A native of Trenton, Canada, Dr. Tessier-Lavigne obtained his Ph.D. from University College London and performed postdoctoral work at the Medical Research Council (United Kingdom) Developmental Neurobiology Unit and at Columbia University.  He has been on the faculty of the University of California, San Francisco and Stanford University and has been a Howard Hughes Medical Institute investigator.  In 2003, he joined Genentech, where he oversaw 1,400 people in disease research and drug discovery.  He is the recipient of numerous scientific awards and is an elected member of the U.S. National Academy of Sciences and its Institute of Medicine, and a fellow of the Royal Societies of the U.K. and Canada.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products, ARCALYST® (rilonacept) Injection For Subcutaneous Use and EYLEA™ (aflibercept) Injection.  Regeneron also has completed several Phase 3 studies and is conducting an additional Phase 3 clinical trial for the product candidate ZALTRAP® (aflibercept) concentrate for Intravenous Infusion.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on the Regeneron web site at www.regeneron.com.

Forward Looking StatementThis news release includes forward-looking statements about Regeneron and its products, development programs, finances, and business, all of which involve a number of risks and uncertainties.  These include, among others, risks and timing associated with preclinical and clinical development of Regeneron's drug candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its products and drug candidates, competing drugs that are superior to Regeneron's products and drug candidates, uncertainty of market acceptance of Regeneron's products and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission (SEC), including its Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended September 30, 2011.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Contact Information:  

 Michael Aberman, M.D. 

Peter DworkinInvestor RelationsCorporate Communications914.847.7799914.847.764michael.aberman@regeneron.com

peter.dworkin@regeneron.com


'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimers Disease
2. The Blanchette Rockefeller Neurosciences Institute Identifies Groundbreaking New Therapies for Prevention and Treatment of Alzheimers Disease
3. EHE International Showcases The National Tourette Syndrome Association, Inc. with Month-Long Window Display in Rockefeller Center Plaza
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Boston University Biomedical Engineers Find Chink in Bacterias Armor
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Potential Breakthrough Cancer Treatment Emerges from MIPS-Funded Clinical Trial Teaming CSA Medical Inc. and University of Maryland Researchers
8. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
9. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
10. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
11. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
Breaking Medicine News(10 mins):